Nine-valent HPV vaccine - new generation of HPV vaccine

Authors: T. Fait 1,2 ;  V. Dvořák 1,4;  R. Pilka 1,3
Authors‘ workplace: HPV College o. s., prezident MUDr. J. Ondruš, CSc., MIAC 1;  Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha, přednosta prof. MUDr. A. Martan, DrSc. 2;  Porodnicko-gynekologická klinika FN a LP UP, Olomouc, přednosta prof. MUDr. R. Pilka, Ph. D. 3;  Centrum ambulantní gynekologie a primární péče, Brno 4
Published in: Ceska Gynekol 2015; 80(6): 397-400


To evaluate current knowledge about new generation of HPV vaccine – nine-valent vaccine Gardasil9.

Review article.

The nine-valent vaccine against HPV 6/11/16/18/31/33/45/52/58 could improve efficacy of quadrivalent vaccine from 70 to 90 percent for cervical cancer. In addition this vaccine has covered around85-90% of HPV-related vulvar, vaginal and anal cancers. Efficacy and immunogenicity against HPV 6/11/16/18 is the same as for quadrivalent vaccine. Efficacy against HPV 31/33/45/52/58 associated lesions is 97%.

HPV infection, prevention, nine-valent HPV vaccine


1. Castellsague, X., Guiliano, A., Goldstone, S., et al. Tolerability and immunogenicity of a multivalent HPV L1 virus-lik partije vaccine in 16- to 26-year old men. Eurogin, 2015, abstract, p. 174.

2. Joura, AE., Guiliano, AR., Iversen, O., et al. A 9-valent HPV vaccne infekcion and intraepitelial neoplasia in woman. N Engl J Med, 2015, 372(8), p. 711–723.

3. Malagón, T., Drolet, M., Boily, MC., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis, 2012, 12, p. 781–789.

4. Pills, S., Joura, E. From the monovalent to the nine-valent HPV vaccine. Clin Microbiol Infect, 2015, 21(9), p. 827–333.

5. Pillsbury, M., Kyle, J., Weiss, T., Brandtmuller, A. Projecting the potential public health impact of 9-valent HPV vaccine in the Czech Republic. Eurogin, 2015, abstract, p. 239.

6. Riethmuller, D., Jacquard, AC., Lacau, SG., et al. Potential impact of a nonavalent HPV vaccine on the occurence of HPV-related diseases in France. BMC Public Health, 2015, 15(1), p. 453.

7. Serrano, B., Alemany, L., Tous, S., et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer, 2012, 7(1), p. 38.

8. Serrano, B., deSanjosé, S., Tous, S., et al. HPV genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 a 58 in female anogenital lesions. Eur J Cancer, 2015, 51(13), p. 1732–1741.

9. Schilling, A., Parra, MM., Gutierrez, M., et al. Coadmnistration of a 9-valent HPV vaccine with meningococcal and Tdap vaccine. Pediatrics, 2015, 136(3), p. 563–572.

10. Tachezy, R., Smahelova, J., Salakova, M., et al. HPV genotype distribution in Czech women an men with diseases etiologically linked to HPV. Plos one, 2011, 6(7), p. e21913.

11. Vesikari, T., Brodszki, N., van Damme, P., et al. A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent HPV L1 virus like particle vaccine (V503) versus Gardasil in 9-15-year-old-girls. Pediatr Infect Dis J, 2015, 34(9), p. 992–998.

Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account